KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Debt (2016 - 2024)

Historic Non-Current Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Q4 2024 value amounting to $51.9 million.

  • Ionis Pharmaceuticals' Non-Current Debt rose 2411.32% to $51.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.9 million, marking a year-over-year increase of 2411.32%. This contributed to the annual value of $51.9 million for FY2024, which is 2411.32% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Non-Current Debt stood at $51.9 million for Q4 2024, which was up 2411.32% from $41.8 million recorded in Q4 2023.
  • In the past 5 years, Ionis Pharmaceuticals' Non-Current Debt registered a high of $60.0 million during Q2 2021, and its lowest value of $8.8 million during Q1 2023.
  • Moreover, its 5-year median value for Non-Current Debt was $59.7 million (2021), whereas its average is $51.7 million.
  • Within the past 5 years, the most significant YoY rise in Ionis Pharmaceuticals' Non-Current Debt was 16191.7% (2023), while the steepest drop was 8518.21% (2023).
  • Ionis Pharmaceuticals' Non-Current Debt (Quarter) stood at $60.0 million in 2020, then dropped by 0.45% to $59.7 million in 2021, then plummeted by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then increased by 24.11% to $51.9 million in 2024.
  • Its Non-Current Debt was $51.9 million in Q4 2024, compared to $41.8 million in Q4 2023 and $8.8 million in Q1 2023.